Alnylam Pharmaceuticals’ Educational Grants fund independent educational projects advancing clinical knowledge in ATTR amyloidosis, AHP, and PH1.
Alnylam Pharmaceuticals' CME Grants fund independent, evidence-based education for healthcare professionals on ATTR amyloidosis, AHP, and PH1.
AstraZeneca funds independent medical education programs to improve awareness, diagnosis, and treatment knowledge of transthyretin amyloidosis for multidisciplinary healthcare professionals.
Alnylam Pharmaceuticals' Sponsorships fund educational and scientific initiatives advancing research and awareness in ATTR amyloidosis, AHP, and PH1.
Alnylam Pharmaceuticals’ Collaborative Projects Support grant funds joint research and educational projects focused on advancing science in ATTR amyloidosis, AHP, and PH1.